Stocks

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company …

Western Union (NYSE:WU) First Quarter 2024 Results Key Financial Results Revenue: US$1.05b (up 1.2% from 1Q 2023). Net income: US$142.7m (down 6.0% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). EPS: US$0.41. earnings-and-revenue-growth All figures shown in the chart above are …

Net Income: $15.1 million Earnings Per Share (EPS): $0.15 Adjusted Net Income: $13.9 million Adjusted EPS: $0.14 Revenue: $599 million Operating Income Growth: Up 37% year-over-year Revenue Growth: Up 12% year-over-year Adjusted EBITDA: $61.7 million ROV Revenue per Day: $10,009 ROV Utilization: 64% ROV …

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital …

MILWAUKEE, April 26, 2024--(BUSINESS WIRE)--Rockwell Automation, Inc. (NYSE: ROK) Senior Vice President, Lifecycle Services, Matt Fordenwalt, and Vice President, Investor Relations and Market Strategy, Aijana Zellner, will present virtually at Oppenheimer’s 19th Annual Industrial Growth Conference on Wednesday, May 8, 2024. The fireside chat …

Turnaround Gains Momentum As Sales Improve Sequentially Gross and Operating Margin Expand Significantly Versus Prior Year Operating Cash Flow Increases Versus Prior Year Affirms Outlook for Full Year 2024 ATLANTA, April 26, 2024--(BUSINESS WIRE)--Newell Brands (NASDAQ: NWL) today announced its first quarter 2024 financial …

Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy alone in cisplatin-eligible adults with unresectable or metastatic urothelial carcinoma If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy …